November 3, 2020
IRAK4 Degrader to Take on Innate Immunity
Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020)
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 15, 2020
Targeted Protein Degradation Beyond Oncology
3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Mainolfi
Read More
October 14, 2020
PK/PD Relationship in Targeted Protein Degradation
3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Rong
Read More
October 9, 2020
Interim results from non-interventional study to evaluate cutaneous and circulating biomarkers for a novel IRAK4-targeted therapeutic in patients with hidradenitis suppurativa
5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
Hidradenitis Suppurativa (HS)
Read More
June 22, 2020
IRAKIMiDs: Protein degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broad activity with durable regressions in MYD88 mutant lymphoma xenografts in vivo
American Association for Cancer Research (AACR) Virtual Annual Meeting II
MYD88 Tumors
Read More
June 22, 2020
A STAT3-selective targeted protein degrader decreases the immune-suppressive tumor microenvironment and drives anti-tumor activity in preclinical models
American Association for Cancer Research (AACR) Virtual Annual Meeting II
Liquid Tumors
Solid Tumors
Read More
February 5, 2020
Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa
European Hidradenitis Suppurativa Foundation Scientific Conference
Hidradenitis Suppurativa (HS)
Read More
December 7, 2019
Small molecule-induced, selective STAT3 degradation leads to anti-tumor activity in STAT3-dependent heme malignancies
American Society of Hematology (ASH) Annual Meeting
Liquid Tumors
Read More
November 8, 2019
A first-in-class selective and potent IRAK4 degrader demonstrates robust in vitro and in vivo inhibition of TLR/IL-1R activation and inflammation
American College of Rheumatology Annual Meeting
Read More
October 26, 2019
Discovery of KYM-003, a potent and selective STAT3 degrader with anti-tumor activity in heme malignancies
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Liquid Tumors
Read More